查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1948937

緩激肽受體拮抗劑市場按類型、適應症、給藥途徑和最終用戶分類，全球預測，2026-2032年

Bradykinin Receptor Antagonists Market by Type, Indication, Route Of Administration, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，緩激肽受體拮抗劑市場價值將達到 2.0517 億美元，到 2026 年將成長至 2.3099 億美元，到 2032 年將達到 5.2545 億美元，複合年成長率為 14.37%。

關鍵市場統計數據
基準年 2025 2.0517億美元
預計年份：2026年 2.3099億美元
預測年份 2032 5.2545億美元
複合年成長率 (%) 14.37%

分析科學進展和發展趨勢如何重塑緩激肽受體拮抗劑在臨床和商業領域的治療方法。

緩激肽受體拮抗劑已成為治療創新領域的研究熱點，可用於治療從血管滲透性到傷害感受等多種病理學過程。分子藥理學的最新進展，以及先進的遞送技術，加速了拮抗劑向臨床計畫的轉化，這些計畫旨在治療慢性咳嗽、遺傳性血管性水腫和糖尿病腎臟病等疾病。這些進展反映了治療策略轉變為機制主導療法的趨勢，這種療法優先考慮受體選擇性、最佳化的藥物動力學和以患者為中心的給藥途徑。

科學突破、遞送技術創新和不斷發展的商業性夥伴關係如何融合，正在重新定義緩激肽受體拮抗劑的研發路徑

由於科學、技術和商業三大力量的融合，緩激肽受體拮抗劑領域正經歷著變革性的轉變。在科學方面，結構生物學和動態的進步正在完善標靶結合模式，使研發人員能夠設計出選擇性更高、脫靶效應更低的抗體和胜肽。同時，藥物化​​學的進步正在開發出生物利用度和組織滲透性更佳的小分子，從而拓展了口服療法的可能性。

評估美國關稅變化對緩激肽受體拮抗劑原料採購、製造地和供應鏈韌性的累積影響

2025年，美國實施的關稅政策導致全球供應鏈重組，直接影響了緩激肽受體拮抗劑的研發和商業化。其累積影響體現在多個方面，包括活性藥物成分的採購、關鍵生物製藥材料的採購以及專用生產設備的跨境流動。這些趨勢凸顯了採購多元化策略和近岸外包方案對於維持臨床生產和商業供應連續性的重要性。

整合治療方式、差異化臨床適應症、給藥途徑、通路和終端用戶環境，以挖掘可操作的細分資訊。

對緩激肽受體拮抗劑領域進行詳細的細分，對於理解該領域研發和商業化策略的多樣性至關重要。從產品類型檢驗，此領域可分為兩大類：生物製藥和小分子藥物。在生物製藥領域，研發人員主要關注單株抗體和胜肽類藥物，這兩種藥物的免疫抗原性原性、製劑需求和監管要求各不相同。這些治療方法差異會影響臨床試驗設計、患者選擇、生產複雜性和低溫運輸要求。

區域策略和監管因素將決定全球市場的臨床開發優先順序、准入途徑和商業化策略。

區域趨勢將影響緩激肽受體拮抗劑的臨床開發方案、定價策略和進入途徑，美洲、歐洲、中東和非洲以及亞太地區需要不同的策略。在美洲，完善的臨床試驗基礎設施和成熟的專科醫療網路支援對新型拮抗劑進行快速評估，而支付方體系則傾向於強調可證實的真實世界療效和相對價值。這種環境有利於那些能夠迅速闡明患者獲益和成本效益的項目，從而確保藥物被納入醫保目錄並獲得臨床醫生的採納。

策略聯盟、以模式為中心的創新以及契約製造夥伴關係如何塑造競爭差異化和商業化準備

在緩激肽受體拮抗劑領域營運的公司採用差異化策略，在複雜的創新生態系統中競爭與合作。現有製藥公司利用其規模、監管經驗和全球商業化網路，引導後期研發項目完成核准流程，並與支付方進行交易談判。這些現有公司通常會透過許可和收購來增強其產品線，以獲得特定療法領域的專業知識，尤其是在胜肽類藥物和標靶生物製藥。

為提高緩激肽受體拮抗劑療法的耐受性、加速研發以及確保支付方和醫療服務提供者採納，開發人員可採取切實可行的策略行動。

產業領導者應採取一系列切實可行的措施，將科學進步轉化為永續的競爭優勢。首先，制定針對特定療法的研發藍圖，使生物製藥和小分子藥物的優勢與目標適應症和給藥途徑相匹配，從而降低研發失敗的風險，並加快產品價值實現。其次，透過對關鍵原料的多個供應商進行資格認證、投資區域性生產冗餘以及製定庫存策略以應對關稅和物流波動，來增強供應鏈的韌性。

採用嚴謹的混合方法研究框架，結合相關人員訪談、科學文獻綜述和營運分析，以得出可操作的研究結果。

本分析的研究方法融合了第一手質性研究成果和全面的二次綜合分析，從而得出可靠且可操作的見解。第一手研究包括對藥物發現、臨床開發、生產製造、註冊事務和商業運營等各個環節的相關人員進行結構化訪談，並輔以專家諮詢，以檢驗新出現的假設並識別運營方面的限制因素。這些工作提供了關於治療方式選擇、臨床終點優先排序和區域實施挑戰的實地觀點。

關於如何協調科學創新、運作韌性和證據生成以實現緩激肽受體拮抗劑全部治療潛力的結論性研究結果

總之，緩激肽受體拮抗劑領域正從分子概念概念驗證階段走向臨床差異化且具有商業性可行性的治療方案。生物製藥和小分子化合物的科學進步，以及遞送技術和真實世界數據收集的進步，正在為滿足呼吸系統疾病、腎臟疾病和遺傳性血管性水腫等適應症中尚未得到充分滿足的醫療需求開闢多條途徑。同時，關稅、供應鏈複雜性和區域監管差異等外部壓力要求我們採取積極主動的營運策略，以確保專案按時完成，並保障患者能夠可靠地獲得治療。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 緩激肽受體拮抗劑市場按類型分類

  • 生物製藥
    • 單株抗體
    • 胜肽
  • 低分子化合物

第9章 緩激肽受體拮抗劑市場依適應症分類

  • 慢性咳嗽
    • 特發性咳嗽
    • 頑固性咳嗽
  • 糖尿病腎臟病
  • 遺傳性血管性水腫
    • 急性發作
    • 預防

第10章 緩激肽受體拮抗劑市場依給藥途徑分類

  • 吸入
  • 口服
    • 膠囊
    • 藥片
  • 腸外給藥
    • 靜脈注射
    • 皮下注射
  • 局部用藥

第11章 緩激肽受體拮抗劑市場（依最終用戶分類）

  • 門診治療
    • 診所
    • 診斷中心
  • 居家醫療
    • 居家護理
    • 自我管理
  • 醫院
    • 私立醫院
    • 公立醫院

第12章 緩激肽受體拮抗劑市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 緩激肽受體拮抗劑市場（依類別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 各國緩激肽受體拮抗劑市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

15. 美國緩激肽受體拮抗劑市場

第16章：中國緩激肽受體拮抗劑市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Bayer AG
  • BioCryst Pharmaceuticals, Inc.
  • Boehringer Ingelheim International GmbH
  • CSL Limited
  • Dyax Corp.
  • Elan Pharmaceuticals, Inc.
  • Ionis Pharmaceuticals, Inc.
  • Jerini AG
  • KalVista Pharmaceuticals, Inc.
  • Laboratoires Fournier SA
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Pharming Group NV
  • Pharvaris NV
  • Sanofi SA
  • SIGMA-TAU Industrie Farmaceutiche Riunite SpA
  • Swedish Orphan Biovitrum AB
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-4F7A6D4FB8F5

The Bradykinin Receptor Antagonists Market was valued at USD 205.17 million in 2025 and is projected to grow to USD 230.99 million in 2026, with a CAGR of 14.37%, reaching USD 525.45 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 205.17 million
Estimated Year [2026] USD 230.99 million
Forecast Year [2032] USD 525.45 million
CAGR (%) 14.37%

Navigating the scientific advances and development dynamics that are reshaping therapeutic approaches to bradykinin receptor antagonists across clinical and commercial domains

Bradykinin receptor antagonists have emerged as a focal point of therapeutic innovation, addressing a spectrum of pathophysiologic processes from vascular permeability to nociception. Recent advances in molecular pharmacology, coupled with refined delivery technologies, have accelerated the translation of antagonists into clinical programs targeting conditions such as chronic cough, hereditary angioedema, and diabetic nephropathy. These developments reflect a broader shift toward mechanism-driven therapies that prioritize receptor selectivity, pharmacokinetic optimization, and patient-centric routes of administration.

The competitive landscape spans established biopharmaceutical companies and agile biotechnology ventures advancing both biologic modalities and small molecules. Biologics, including monoclonal antibodies and peptides, have demonstrated potential for high specificity and durable target engagement, while small molecules offer advantages in oral administration and manufacturing scalability. As a result, clinical development strategies are increasingly hybrid, leveraging strengths of each modality to meet differing clinical needs and commercial constraints. Regulatory authorities are also adapting review frameworks to accommodate novel modalities and combination approaches, which affects program design and go-to-market planning.

In this context, stakeholders must integrate scientific promise with pragmatic considerations such as supply chain resilience, access pathways, and evidence generation strategies. The imperative is clear: align discovery and development priorities with delivery models and health system dynamics to translate molecular innovation into meaningful patient outcomes.

How converging scientific breakthroughs, delivery technology innovations, and evolving commercial partnerships are redefining development pathways for bradykinin receptor antagonists

The landscape for bradykinin receptor antagonists is undergoing transformative shifts driven by converging scientific, technological, and commercial forces. On the scientific front, improvements in structural biology and pharmacodynamics have refined target engagement paradigms, enabling developers to design antibodies and peptides with enhanced selectivity and reduced off-target effects. Concurrently, advances in medicinal chemistry are producing small molecules with improved bioavailability and tissue penetration, expanding the potential for oral therapies.

Technological innovation in drug delivery is also recalibrating expectations for patient adherence and therapeutic persistence. Inhalation platforms and optimized parenteral formulations permit targeted lung delivery and sustained systemic exposure, respectively, while oral dosage forms are being engineered for better stability and absorption. These developments are complemented by digital health tools that support real-world evidence collection and patient monitoring, allowing sponsors to demonstrate value beyond traditional clinical endpoints.

Commercially, the field is moving from single-agent development toward integrated care solutions that consider dosing convenience, healthcare infrastructure, and payer preferences. Partnerships between biotechs and larger pharmaceutical companies are becoming more strategic, focusing on co-development, shared risk models, and global commercialization capabilities. Finally, regulatory agencies are demonstrating greater willingness to engage early with sponsors on adaptive development pathways, creating opportunities to accelerate programs that meet high unmet needs while ensuring robust safety evaluation.

Assessing the cumulative effects of United States tariff changes on raw material sourcing, manufacturing footprints, and supply chain resilience for bradykinin receptor antagonists

In 2025, tariff policies implemented by the United States have contributed to a recalibration of global supply chains that directly affects development and commercialization of bradykinin receptor antagonists. The cumulative impact has manifested across multiple dimensions, including sourcing of active pharmaceutical ingredients, procurement of key biologics raw materials, and cross-border movement of specialized manufacturing equipment. These dynamics have increased the importance of diversified sourcing strategies and nearshoring options to maintain continuity of clinical manufacturing and commercial supply.

Biologics and peptides are particularly sensitive to disruptions in the supply of critical reagents, single-use technologies, and cold-chain logistics. Consequently, some developers have accelerated the qualification of alternate suppliers and invested in regional manufacturing capacity to mitigate tariff-driven cost pressures and logistical delays. Small molecule developers have similarly revisited supplier contracts for intermediates and excipients, with an emphasis on contractual flexibility and inventory management to absorb tariff volatility.

Beyond procurement, tariffs have altered the calculus for where to site scale-up and commercialization operations. Companies are weighing the trade-offs between lower input costs in certain jurisdictions and tariff exposure during cross-border transfers. In response, many are adopting a hybrid production footprint that blends regional fill-finish capabilities with centralized API synthesis or biologic fermentation hubs. Taken together, these adaptations reflect a broader industry imperative to increase operational resilience, preserve development timelines, and maintain predictable access to patients in key markets.

Synthesizing therapeutic modality, clinical indication differentiation, administration routes, distribution pathways, and end-user settings to reveal actionable segmentation intelligence

A granular understanding of segmentation is essential to appreciate the heterogeneity of development and commercialization strategies within the bradykinin receptor antagonist space. When examining product type, the field divides between biologics and small molecule programs; within biologics, developers concentrate on monoclonal antibodies and peptide therapeutics, each presenting distinct immunogenicity profiles, formulation needs, and regulatory considerations. These modality-driven differences influence clinical trial design and patient selection, as well as manufacturing complexity and cold-chain requirements.

Indication-specific segmentation further informs development priorities. Clinical programs target chronic cough, diabetic nephropathy, and hereditary angioedema, where the therapeutic rationale and endpoint architecture vary substantially. Chronic cough programs differentiate between idiopathic cough and refractory cough populations, requiring nuanced diagnostic criteria and patient-reported outcome measures. Hereditary angioedema development distinguishes between treatment of acute attacks and prophylactic regimens, which alters dosing frequency, safety monitoring, and value proposition to payers and care providers.

Route of administration segmentation shapes patient experience and adoption. Inhalation approaches are optimized for respiratory indications, while oral delivery-available in capsule and tablet formats-supports broader outpatient use and self-administration. Parenteral options, whether intravenous or subcutaneous, accommodate severe or rapidly progressive disease courses and often necessitate clinic-based administration or home nursing support. Topical delivery offers localized exposure for niche indications and can lower systemic adverse event profiles.

Distribution channel considerations determine patient access and healthcare integration. Hospital pharmacies manage inpatient and outpatient dispensing for acute and specialty therapies, while online pharmacy models offer direct-to-patient or pharmacy pickup options that enhance convenience. Retail channels span chain and independent pharmacies, which serve as important touchpoints for chronic therapy adherence. Finally, end-user segmentation-ambulatory care settings including clinics and diagnostic centers, home care options such as home nursing and self-administration, and hospital environments encompassing private and public institutions-affects service delivery models, reimbursement interactions, and disease management pathways. Collectively, these intersecting segmentation dimensions guide product design, evidence generation strategies, and commercialization planning in a way that aligns clinical differentiation with operational feasibility.

Regional strategies and regulatory considerations that determine clinical development prioritization, access pathways, and commercialization approaches across global markets

Regional dynamics shape clinical development choices, pricing strategies, and access pathways for bradykinin receptor antagonists, requiring tailored approaches across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, robust clinical trial infrastructures and established specialty care networks support the rapid evaluation of novel antagonists, while payer systems drive an emphasis on demonstrable real-world effectiveness and comparative value. This environment favors programs that can rapidly articulate patient benefit and cost-effectiveness to secure formulary placement and clinician uptake.

In Europe, Middle East & Africa, regulatory heterogeneity and variable healthcare financing models necessitate regionally nuanced market entry strategies. Multi-country regulatory coordination and early engagement with health technology assessment bodies become critical, particularly for biologics that require detailed pharmacoeconomic justification. Many companies therefore adopt phased launches, aligning clinical evidence generation with country-level reimbursement requirements and partnering with regional distributors to navigate complex logistics.

Asia-Pacific presents a diverse landscape where rapid patient enrollment capabilities and growing biomanufacturing ecosystems coexist with varying regulatory pathways. Certain markets prioritize local clinical data and technology transfer commitments, while others offer attractive incentives for establishing production capacity. Consequently, sponsors often pursue strategic collaborations with regional partners to expedite development, secure manufacturing redundancy, and optimize access. Across all regions, stakeholders must balance centralized strategic planning with local execution to align scientific innovation with regulatory realities and patient access considerations.

How strategic alliances, modality-focused innovation, and contract manufacturing partnerships are shaping competitive differentiation and commercialization readiness

Companies active in the bradykinin receptor antagonist arena are adopting differentiated strategies to compete and collaborate in a complex innovation ecosystem. Established pharmaceutical companies leverage scale, regulatory experience, and global commercialization networks to shepherd late-stage assets through registrational pathways and to negotiate payer contracts. These incumbents often pursue licensing or acquisition to augment their pipelines with modality-specific expertise, particularly in peptide therapeutics and targeted biologics.

Smaller biotechnology firms and academic spin-outs focus on early-stage innovation, advancing mechanistic insights into receptor biology and partnering with larger entities to access development capital and manufacturing capabilities. Such collaborations are frequently structured as milestone-driven alliances that align scientific milestones with commercial incentives. Contract development and manufacturing organizations play a pivotal role by offering specialized capabilities such as biologic expression systems, single-use bioreactors, and high-containment fill-finish services, enabling sponsors to compress timelines and manage capital intensity.

Additionally, service providers offering digital health, patient support, and real-world evidence platforms are becoming strategic partners, helping companies demonstrate adherence, safety, and long-term outcomes necessary for payer acceptance. Across these players, successful companies combine scientific differentiation with operational agility, prioritizing scalable manufacturing plans, robust clinical endpoints, and proactive stakeholder engagement to navigate regulatory and reimbursement landscapes effectively.

Practical strategic actions for developers to strengthen resilience, accelerate development, and secure payer and provider adoption of bradykinin receptor antagonist therapies

Industry leaders should adopt a set of actionable measures to translate scientific progress into sustainable competitive advantage. First, integrate modality-tailored development roadmaps that align biologic and small molecule strengths with intended indications and administration routes; doing so reduces attrition risk and accelerates time-to-value. Second, strengthen supply chain resilience by qualifying multiple suppliers for critical materials, investing in regional manufacturing redundancy, and designing inventory strategies that absorb tariff and logistics variability.

Third, prioritize evidence strategies that go beyond traditional randomized trials to include real-world data collection, patient-reported outcomes, and health economic modeling; these elements will be decisive in payer negotiations and formulary decisions. Fourth, pursue pragmatic commercialization partnerships that combine local market expertise with global distribution capabilities, enabling phased rollouts that align regulatory approval timelines with reimbursement readiness. Fifth, leverage digital tools to support adherence, remote monitoring, and decentralized trial components, which improve patient engagement and generate longitudinal outcomes data.

Finally, foster regulatory engagement early and continuously, using parallel scientific advice and adaptive trial designs where appropriate. By executing on these recommendations, organizations can reduce development complexity, enhance patient access, and increase the probability that a promising molecular concept becomes a commercially viable therapeutic option.

A rigorous mixed-methods research framework combining stakeholder interviews, scientific literature synthesis, and operational analysis to produce actionable intelligence

The research approach underpinning this analysis blends primary qualitative insights with comprehensive secondary synthesis to produce robust, actionable intelligence. Primary research included structured interviews with stakeholders across discovery, clinical development, manufacturing, regulatory affairs, and commercial operations, complemented by expert advisory consultations to validate emerging hypotheses and identify operational constraints. These engagements provided frontline perspectives on modality selection, clinical endpoint prioritization, and regional execution challenges.

Secondary research synthesized peer-reviewed literature, regulatory guidelines, public company disclosures, and industry technical reports to trace scientific evolution and platform capabilities. Emphasis was placed on triangulating data across sources to ensure factual accuracy and to identify consistent themes. Analytical frameworks encompassed modality risk profiling, supply chain stress-testing, and go-to-market readiness assessments, which were applied to individual therapeutic candidates and program archetypes.

Data synthesis prioritized transparency in assumptions and reproducibility of conclusions. Where expert opinion informed interpretation, the methodology documented the rationale and confidence level. The resulting analysis therefore combines empirical evidence with practitioner judgment to deliver strategic recommendations that are both rigorous and operationally relevant.

Concluding insights on aligning scientific innovation, operational resilience, and evidence generation to realize the full therapeutic potential of bradykinin receptor antagonists

In summary, the bradykinin receptor antagonist field is maturing from molecular proof-of-concept toward clinically differentiated and commercially viable therapeutic options. Scientific progress in both biologic and small molecule domains, paired with advances in delivery and real-world data capture, creates multiple pathways to address high unmet needs across respiratory, renal, and hereditary angioedema indications. At the same time, external pressures such as tariffs, supply chain complexities, and regional regulatory heterogeneity require proactive operational strategies to preserve program timelines and ensure reliable patient access.

To succeed, organizations must align modality choice with indication-specific demands, construct resilient manufacturing and procurement architectures, and generate multi-dimensional evidence that satisfies clinicians, payers, and patients. Strategic collaborations that combine innovation with scale, alongside intelligent use of digital tools and decentralized approaches, will accelerate the translation of promising compounds into standard-of-care options. Ultimately, the capacity to integrate scientific differentiation with pragmatic commercialization and access planning will determine which programs achieve enduring clinical and market impact.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Bradykinin Receptor Antagonists Market, by Type

  • 8.1. Biologic
    • 8.1.1. MAb
    • 8.1.2. Peptide
  • 8.2. Small Molecule

9. Bradykinin Receptor Antagonists Market, by Indication

  • 9.1. Chronic Cough
    • 9.1.1. Idiopathic Cough
    • 9.1.2. Refractory Cough
  • 9.2. Diabetic Nephropathy
  • 9.3. Hereditary Angioedema
    • 9.3.1. Acute Attack
    • 9.3.2. Prophylaxis

10. Bradykinin Receptor Antagonists Market, by Route Of Administration

  • 10.1. Inhalation
  • 10.2. Oral
    • 10.2.1. Capsule
    • 10.2.2. Tablet
  • 10.3. Parenteral
    • 10.3.1. IV
    • 10.3.2. SC
  • 10.4. Topical

11. Bradykinin Receptor Antagonists Market, by End User

  • 11.1. Ambulatory Care
    • 11.1.1. Clinics
    • 11.1.2. Diagnostic Centers
  • 11.2. Home Care
    • 11.2.1. Home Nursing
    • 11.2.2. Self Administration
  • 11.3. Hospital
    • 11.3.1. Private Hospital
    • 11.3.2. Public Hospital

12. Bradykinin Receptor Antagonists Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Bradykinin Receptor Antagonists Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Bradykinin Receptor Antagonists Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Bradykinin Receptor Antagonists Market

16. China Bradykinin Receptor Antagonists Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. Bayer AG
  • 17.7. BioCryst Pharmaceuticals, Inc.
  • 17.8. Boehringer Ingelheim International GmbH
  • 17.9. CSL Limited
  • 17.10. Dyax Corp.
  • 17.11. Elan Pharmaceuticals, Inc.
  • 17.12. Ionis Pharmaceuticals, Inc.
  • 17.13. Jerini AG
  • 17.14. KalVista Pharmaceuticals, Inc.
  • 17.15. Laboratoires Fournier S.A.
  • 17.16. Merck & Co., Inc.
  • 17.17. Novartis AG
  • 17.18. Pfizer Inc.
  • 17.19. Pharming Group N.V.
  • 17.20. Pharvaris N.V.
  • 17.21. Sanofi S.A.
  • 17.22. SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A.
  • 17.23. Swedish Orphan Biovitrum AB
  • 17.24. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY BIOLOGIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY BIOLOGIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY BIOLOGIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY MAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY MAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY MAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY PEPTIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY PEPTIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY PEPTIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY SMALL MOLECULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY SMALL MOLECULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY CHRONIC COUGH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY CHRONIC COUGH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY CHRONIC COUGH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY CHRONIC COUGH, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY IDIOPATHIC COUGH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY IDIOPATHIC COUGH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY IDIOPATHIC COUGH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY REFRACTORY COUGH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY REFRACTORY COUGH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY REFRACTORY COUGH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY DIABETIC NEPHROPATHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY DIABETIC NEPHROPATHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY DIABETIC NEPHROPATHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY ACUTE ATTACK, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY ACUTE ATTACK, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY ACUTE ATTACK, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY PROPHYLAXIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY PROPHYLAXIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY PROPHYLAXIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY INHALATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY INHALATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY TABLET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY TABLET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY IV, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY IV, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY IV, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY SC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY SC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY SC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY AMBULATORY CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY AMBULATORY CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY AMBULATORY CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY AMBULATORY CARE, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HOME NURSING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HOME NURSING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HOME NURSING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY SELF ADMINISTRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY SELF ADMINISTRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY SELF ADMINISTRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY PRIVATE HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY PRIVATE HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY PRIVATE HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY PUBLIC HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY PUBLIC HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY PUBLIC HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY CHRONIC COUGH, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY AMBULATORY CARE, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY CHRONIC COUGH, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY AMBULATORY CARE, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY CHRONIC COUGH, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY AMBULATORY CARE, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY CHRONIC COUGH, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY AMBULATORY CARE, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY CHRONIC COUGH, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY AMBULATORY CARE, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. MIDDLE EAST BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY CHRONIC COUGH, 2018-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 172. MIDDLE EAST BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 174. MIDDLE EAST BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY AMBULATORY CARE, 2018-2032 (USD MILLION)
  • TABLE 175. MIDDLE EAST BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 177. AFRICA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. AFRICA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. AFRICA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 180. AFRICA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 181. AFRICA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY CHRONIC COUGH, 2018-2032 (USD MILLION)
  • TABLE 182. AFRICA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2032 (USD MILLION)
  • TABLE 183. AFRICA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 184. AFRICA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 185. AFRICA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 186. AFRICA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 187. AFRICA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY AMBULATORY CARE, 2018-2032 (USD MILLION)
  • TABLE 188. AFRICA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
  • TABLE 189. AFRICA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 191. ASIA-PACIFIC BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 194. ASIA-PACIFIC BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY CHRONIC COUGH, 2018-2032 (USD MILLION)
  • TABLE 195. ASIA-PACIFIC BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2032 (USD MILLION)
  • TABLE 196. ASIA-PACIFIC BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 197. ASIA-PACIFIC BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 198. ASIA-PACIFIC BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 199. ASIA-PACIFIC BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 200. ASIA-PACIFIC BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY AMBULATORY CARE, 2018-2032 (USD MILLION)
  • TABLE 201. ASIA-PACIFIC BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
  • TABLE 202. ASIA-PACIFIC BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 203. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 204. ASEAN BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. ASEAN BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. ASEAN BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 207. ASEAN BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 208. ASEAN BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY CHRONIC COUGH, 2018-2032 (USD MILLION)
  • TABLE 209. ASEAN BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2032 (USD MILLION)
  • TABLE 210. ASEAN BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 211. ASEAN BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 212. ASEAN BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 213. ASEAN BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 214. ASEAN BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY AMBULATORY CARE, 2018-2032 (USD MILLION)
  • TABLE 215. ASEAN BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
  • TABLE 216. ASEAN BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 217. GCC BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 218. GCC BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. GCC BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 220. GCC BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 221. GCC BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY CHRONIC COUGH, 2018-2032 (USD MILLION)
  • TABLE 222. GCC BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2032 (USD MILLION)
  • TABLE 223. GCC BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 224. GCC BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 225. GCC BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 226. GCC BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 227. GCC BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY AMBULATORY CARE, 2018-2032 (USD MILLION)
  • TABLE 228. GCC BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
  • TABLE 229. GCC BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPEAN UNION BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPEAN UNION BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPEAN UNION BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPEAN UNION BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPEAN UNION BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY CHRONIC COUGH, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPEAN UNION BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPEAN UNION BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPEAN UNION BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPEAN UNION BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPEAN UNION BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPEAN UNION BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY AMBULATORY CARE, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPEAN UNION BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPEAN UNION BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 243. BRICS BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 244. BRICS BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 245. BRICS BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 246. BRICS BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 247. BRICS BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY CHRONIC COUGH, 2018-2032 (USD MILLION)
  • TABLE 248. BRICS BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2032 (USD MILLION)
  • TABLE 249. BRICS BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 250. BRICS BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 251. BRICS BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 252. BRICS BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 253. BRICS BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY AMBULATORY CARE, 2018-2032 (USD MILLION)
  • TABLE 254. BRICS BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
  • TABLE 255. BRICS BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 256. G7 BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 257. G7 BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 258. G7 BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 259. G7 BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 260. G7 BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY CHRONIC COUGH, 2018-2032 (USD MILLION)
  • TABLE 261. G7 BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2032 (USD MILLION)
  • TABLE 262. G7 BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 263. G7 BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 264. G7 BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 265. G7 BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 266. G7 BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY AMBULATORY CARE, 2018-2032 (USD MILLION)
  • TABLE 267. G7 BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
  • TABLE 268. G7 BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 269. NATO BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 270. NATO BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 271. NATO BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 272. NATO BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 273. NATO BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY CHRONIC COUGH, 2018-2032 (USD MILLION)
  • TABLE 274. NATO BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2032 (USD MILLION)
  • TABLE 275. NATO BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 276. NATO BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 277. NATO BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 278. NATO BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 279. NATO BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY AMBULATORY CARE, 2018-2032 (USD MILLION)
  • TABLE 280. NATO BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
  • TABLE 281. NATO BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 282. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 283. UNITED STATES BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 284. UNITED STATES BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 285. UNITED STATES BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 286. UNITED STATES BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 287. UNITED STATES BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY CHRONIC COUGH, 2018-2032 (USD MILLION)
  • TABLE 288. UNITED STATES BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2032 (USD MILLION)
  • TABLE 289. UNITED STATES BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 290. UNITED STATES BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 291. UNITED STATES BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 292. UNITED STATES BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 293. UNITED STATES BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY AMBULATORY CARE, 2018-2032 (USD MILLION)
  • TABLE 294. UNITED STATES BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
  • TABLE 295. UNITED STATES BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 296. CHINA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 297. CHINA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 298. CHINA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 299. CHINA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 300. CHINA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY CHRONIC COUGH, 2018-2032 (USD MILLION)
  • TABLE 301. CHINA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2032 (USD MILLION)
  • TABLE 302. CHINA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 303. CHINA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 304. CHINA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 305. CHINA BRADYKININ RECEPTOR ANTAGONISTS MA